203 related articles for article (PubMed ID: 27576689)
21. Kinetic, stability, and structural changes in high-resolution crystal structures of HIV-1 protease with drug-resistant mutations L24I, I50V, and G73S.
Liu F; Boross PI; Wang YF; Tozser J; Louis JM; Harrison RW; Weber IT
J Mol Biol; 2005 Dec; 354(4):789-800. PubMed ID: 16277992
[TBL] [Abstract][Full Text] [Related]
22. A contribution to the drug resistance mechanism of darunavir, amprenavir, indinavir, and saquinavir complexes with HIV-1 protease due to flap mutation I50V: a systematic MM-PBSA and thermodynamic integration study.
Leonis G; Steinbrecher T; Papadopoulos MG
J Chem Inf Model; 2013 Aug; 53(8):2141-53. PubMed ID: 23834142
[TBL] [Abstract][Full Text] [Related]
23. Molecular basis for substrate recognition and drug resistance from 1.1 to 1.6 angstroms resolution crystal structures of HIV-1 protease mutants with substrate analogs.
Tie Y; Boross PI; Wang YF; Gaddis L; Liu F; Chen X; Tozser J; Harrison RW; Weber IT
FEBS J; 2005 Oct; 272(20):5265-77. PubMed ID: 16218957
[TBL] [Abstract][Full Text] [Related]
24. Molecular analysis of the HIV-1 resistance development: enzymatic activities, crystal structures, and thermodynamics of nelfinavir-resistant HIV protease mutants.
Kozísek M; Bray J; Rezácová P; Sasková K; Brynda J; Pokorná J; Mammano F; Rulísek L; Konvalinka J
J Mol Biol; 2007 Dec; 374(4):1005-16. PubMed ID: 17977555
[TBL] [Abstract][Full Text] [Related]
25. Exploring the drug resistance of V32I and M46L mutant HIV-1 protease to inhibitor TMC114: flap dynamics and binding mechanism.
Meher BR; Wang Y
J Mol Graph Model; 2015 Mar; 56():60-73. PubMed ID: 25562662
[TBL] [Abstract][Full Text] [Related]
26. Spin labeling and Double Electron-Electron Resonance (DEER) to Deconstruct Conformational Ensembles of HIV Protease.
Casey TM; Fanucci GE
Methods Enzymol; 2015; 564():153-87. PubMed ID: 26477251
[TBL] [Abstract][Full Text] [Related]
27. Combining mutations in HIV-1 protease to understand mechanisms of resistance.
Mahalingam B; Boross P; Wang YF; Louis JM; Fischer CC; Tozser J; Harrison RW; Weber IT
Proteins; 2002 Jul; 48(1):107-16. PubMed ID: 12012342
[TBL] [Abstract][Full Text] [Related]
28. Exploring the flap dynamics of the South African HIV subtype C protease in presence of FDA-approved inhibitors: MD study.
Maphumulo SI; Halder AK; Govender T; Maseko S; Maguire GEM; Honarparvar B; Kruger HG
Chem Biol Drug Des; 2018 Nov; 92(5):1899-1913. PubMed ID: 30003668
[TBL] [Abstract][Full Text] [Related]
29. How Mutations Can Resist Drug Binding yet Keep HIV-1 Protease Functional.
Appadurai R; Senapati S
Biochemistry; 2017 Jun; 56(23):2907-2920. PubMed ID: 28505418
[TBL] [Abstract][Full Text] [Related]
30. Role of invariant Thr80 in human immunodeficiency virus type 1 protease structure, function, and viral infectivity.
Foulkes JE; Prabu-Jeyabalan M; Cooper D; Henderson GJ; Harris J; Swanstrom R; Schiffer CA
J Virol; 2006 Jul; 80(14):6906-16. PubMed ID: 16809296
[TBL] [Abstract][Full Text] [Related]
31. Cantilever-centric mechanism of cooperative non-active site mutations in HIV protease: Implications for flap dynamics.
Sherry D; Worth R; Ismail ZS; Sayed Y
J Mol Graph Model; 2021 Jul; 106():107931. PubMed ID: 34030114
[TBL] [Abstract][Full Text] [Related]
32. Exploring molecular mechanism of allosteric inhibitor to relieve drug resistance of multiple mutations in HIV-1 protease by enhanced conformational sampling.
Chen J; Peng C; Wang J; Zhu W
Proteins; 2018 Dec; 86(12):1294-1305. PubMed ID: 30260044
[TBL] [Abstract][Full Text] [Related]
33. A molecular dynamics study comparing a wild-type with a multiple drug resistant HIV protease: differences in flap and aspartate 25 cavity dimensions.
Seibold SA; Cukier RI
Proteins; 2007 Nov; 69(3):551-65. PubMed ID: 17623840
[TBL] [Abstract][Full Text] [Related]
34. Mechanism of drug resistance revealed by the crystal structure of the unliganded HIV-1 protease with F53L mutation.
Liu F; Kovalevsky AY; Louis JM; Boross PI; Wang YF; Harrison RW; Weber IT
J Mol Biol; 2006 May; 358(5):1191-9. PubMed ID: 16569415
[TBL] [Abstract][Full Text] [Related]
35. Understanding the HIV-1 protease nelfinavir resistance mutation D30N in subtypes B and C through molecular dynamics simulations.
Soares RO; Batista PR; Costa MG; Dardenne LE; Pascutti PG; Soares MA
J Mol Graph Model; 2010 Sep; 29(2):137-47. PubMed ID: 20541446
[TBL] [Abstract][Full Text] [Related]
36. Structural characterization of B and non-B subtypes of HIV-protease: insights into the natural susceptibility to drug resistance development.
Sanches M; Krauchenco S; Martins NH; Gustchina A; Wlodawer A; Polikarpov I
J Mol Biol; 2007 Jun; 369(4):1029-40. PubMed ID: 17467738
[TBL] [Abstract][Full Text] [Related]
37. Exploring the drug resistance mechanism of active site, non-active site mutations and their cooperative effects in CRF01_AE HIV-1 protease: molecular dynamics simulations and free energy calculations.
C S V; Tamizhselvi R; Munusami P
J Biomol Struct Dyn; 2019 Jul; 37(10):2608-2626. PubMed ID: 30051758
[TBL] [Abstract][Full Text] [Related]
38. Insights into amprenavir resistance in E35D HIV-1 protease mutation from molecular dynamics and binding free-energy calculations.
Meiselbach H; Horn AH; Harrer T; Sticht H
J Mol Model; 2007 Feb; 13(2):297-304. PubMed ID: 16794810
[TBL] [Abstract][Full Text] [Related]
39. Structural basis for distinctions between substrate and inhibitor specificities for feline immunodeficiency virus and human immunodeficiency virus proteases.
Lin YC; Beck Z; Morris GM; Olson AJ; Elder JH
J Virol; 2003 Jun; 77(12):6589-600. PubMed ID: 12767979
[TBL] [Abstract][Full Text] [Related]
40. Structural studies of FIV and HIV-1 proteases complexed with an efficient inhibitor of FIV protease.
Li M; Morris GM; Lee T; Laco GS; Wong CH; Olson AJ; Elder JH; Wlodawer A; Gustchina A
Proteins; 2000 Jan; 38(1):29-40. PubMed ID: 10651036
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
